A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 24 Weeks in Participants With Eosinophilic Asthma
Latest Information Update: 19 Jun 2025
At a glance
- Drugs Dexpramipexole (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms EXHALE-4
- Sponsors Areteia Therapeutics
Most Recent Events
- 13 Jun 2025 Planned number of patients changed from 550 to 600.
- 11 Apr 2025 Planned End Date changed from 1 Apr 2025 to 1 Dec 2025.
- 11 Apr 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Sep 2025.